Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2026-02-24 @ 12:13 AM
Study NCT ID:
NCT03102450
Status:
COMPLETED
Last Update Posted:
2020-02-26
First Post:
2017-03-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 151}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-12-26', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-02', 'completionDateStruct': {'date': '2019-10-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-02-25', 'studyFirstSubmitDate': '2017-03-27', 'studyFirstSubmitQcDate': '2017-03-30', 'lastUpdatePostDateStruct': {'date': '2020-02-26', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-04-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-10-17', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Contraceptive Efficacy- PI over up to 12 months - typical use', 'timeFrame': 'up to 12 months after the inclusion', 'description': "Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of typical use. The Pearl Index is defined as the number of unintended pregnancies per 100 woman-years of a contraceptive method's use\n\n* Success: no fertilisation\n* Failure: unintended fertilisation (pregnancy or aborted pregnancy)"}], 'secondaryOutcomes': [{'measure': 'Contraceptive Efficacy - PI over up to 12 months - perfect use', 'timeFrame': 'up to 12 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of perfect use'}, {'measure': 'Contraceptive Efficacy - PI over up to 6 months - typical use', 'timeFrame': 'up to 6 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of typical use'}, {'measure': 'Contraceptive Efficacy - PI over up to 6 months - perfect use', 'timeFrame': 'up to 6 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of perfect use'}, {'measure': 'Contraceptive Efficacy - Pregnancy rate over up to 6 months - typical use', 'timeFrame': 'up to 6 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of typical use at Visit 3 (M6)'}, {'measure': 'Contraceptive Efficacy - Pregnancy rate over up to 6 months - perfect use', 'timeFrame': 'up to 6 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of perfect use at Visit 3 (M6)'}, {'measure': 'Contraceptive Efficacy - Pregnancy rate over up to 12 months - typical use', 'timeFrame': 'up to 12 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of typical use at Visit 4 (M12)'}, {'measure': 'Contraceptive Efficacy - Pregnancy rate over up to 12 months - perfect use', 'timeFrame': 'up to 12 months after the inclusion', 'description': 'Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of perfect use at Visit 4 (M12)'}, {'measure': 'Number of adverse events', 'timeFrame': '6 or 12 months after the inclusion', 'description': 'Number of adverse events during the study'}, {'measure': 'Percentage of adverse events', 'timeFrame': '6 or 12 months after the inclusion', 'description': 'Percentage of adverse events during the study'}, {'measure': 'Acceptability - percentage of continuation', 'timeFrame': 'up to 6 or 12 months after the inclusion', 'description': 'Evaluation of the acceptability of the treatment by percentage of continuation until the end of follow-up (at 6 months for all the women and at 12 months for women who have accepted to continue at visit 3 (M6))'}, {'measure': 'Acceptability - adherence', 'timeFrame': 'up to 6 or 12 months after the inclusion', 'description': 'Evaluation of the acceptability of the treatment through adherence: systematic use of benzalkonium chloride spermicide before each event of sexual intercourse recorded in the self-evaluation diary'}, {'measure': 'Acceptability - ease of use (Likert scale)', 'timeFrame': 'up to 6 or 12 months after the inclusion', 'description': 'Evaluation of the acceptability of the treatment (ease of use) evaluated through the self-evaluation diary (Likert scale) up to M6 (V3) and up to M12 (V4) for women who have continued for 12 months'}, {'measure': 'Acceptability - lubricating effect (Likert scale)', 'timeFrame': 'up to 6 or 12 months after the inclusion', 'description': 'Evaluation of the acceptability of the treatment through the lubricating effect (Likert scale) at the end of study visit: V3 (M6), or V4 (M12) or at intermediate visit in case of early withdrawal'}, {'measure': 'Acceptability - global satisfaction of the woman (Likert scale)', 'timeFrame': '1, 2, 4, 6, 9, 12 months after the inclusion', 'description': 'Evaluation of the global satisfaction of the treatment (Likert scale) by the woman at V2 (M2), V3 (M6) and V4 (M12) and during phone contacts PC1 (M1), PC2 (M4) and PC3 (M9)'}, {'measure': 'Acceptability - global satisfaction of the investigator (Likert scale)', 'timeFrame': '2, 6, 12 months after the inclusion', 'description': 'Evaluation of the global satisfaction of the treatment (Likert scale) by the investigator at V2 (M2), V3 (M6) and V4 (M12).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Contraception']}, 'descriptionModule': {'briefSummary': 'In spite of many advantages of spermicides, there is no contraceptive efficacy study conducted with any spermicide in women aged over 40 years. That is why the aim of this study is to evaluate contraceptive efficacy, tolerance and acceptability of a spermicide with benzalkonium chloride (Pharmatex® cream) in women aged over 40 years.', 'detailedDescription': "Not all contraceptive methods are appropriate for all situations, and the most appropriate method of birth control depends on the woman's overall health, her age, the frequency of her sexual activity, her sexual partners, her desire to have children in the future, and personal or family history of certain diseases.\n\nA special interest should be paid to women aged over 40 years. Decreased fertility, increased cardiovascular risks and greater exposure to gynecological disorders during perimenopause have led to reassess the contraceptive methods in this age group. Official guidelines allow the use of any contraceptive method - including combined estrogen progestin contraceptives (COCs) - that it had been well tolerated previously.\n\nHowever, more frequent contraindications during perimenopause can lead women to switch to other methods, such as the intrauterine device, the progestin-only contraception or sterilization. In this context, local contraception with spermicides represents an attractive alternative for perimenopausal women. Being totally safe, particularly metabolically, the use of spermicides in this age group is not restricted by national and international guidelines except in HIV high risk women or women with HIV clinical disease.\n\nFurthermore, the lubricating effect of a galenic formulation of spermicides, such as cream, is particularly useful in cases of vaginal dryness, which is common in perimenopausal women. Lastly, spermicides may be used in combination with other local methods of contraception. Considering the contraindications to other contraceptives, particularly hormonal contraceptives, and the greater risks associated with these methods during perimenopause, spermicides could be an appropriate alternative for a large number of perimenopausal women.\n\nToday, in spite of many advantages of spermicides, there is no contraceptive efficacy study conducted with any spermicide in women aged over 40 years. That is why the aim of this study is to evaluate contraceptive efficacy, tolerance and acceptability of a spermicide with benzalkonium chloride (Pharmatex® cream) in women aged over 40 years."}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Women ≥ 40 years of age, fertile, having had at least one menstrual cycle in the course of the last three months\n2. Women who were informed about the risks and benefits of all contraceptive methods, and for whom contraceptive methods other than spermicides were not suitable\n3. Women who need a contraceptive method and who accept to use a spermicide for at least 6 months.\n4. Women who have a negative pregnancy test at inclusion (the urinary pregnancy test should be performed at investigator's office then confirmed by a blood test performed in a local laboratory (quantitative beta hCG dosage)).))\n5. Women who accept to comply with the requirements of the protocol including visits assessments and diary completion after each sexual intercourse\n6. Women who have had a normal smear test \\< 3 years\n7. Women affiliated to a public health insurance coverage\n8. Women who have read, understood, dated and signed the informed consent form\n\nExclusion Criteria:\n\n1. Women who are not able to understand a birth control method with Pharmatex® cream\n2. Women who have had an unprotected sexual intercourse within 7 days before the Baseline Visit\n3. Allergy or hypersensitivity to one of the components of Pharmatex® cream\n4. Medical contraindication to pregnancy\n5. Abnormal results of cervico-vaginal and/or vulvo-vaginal clinical examination (e.g. severe atrophic vaginitis etc.)\n6. Women with history of \\> 2 induced abortions during lifetime (miscarriages and spontaneous abortions are not included)\n7. Women with history of infectious vaginitis within the last 6 months\n8. Women treated for STI within the last three months\n9. HIV positive women and high-risk women for HIV\n10. Breastfeeding women\n11. Women participating or having participated in a clinical trial within four weeks prior to inclusion\n12. Women deprived of liberty by a legal or administrative decision"}, 'identificationModule': {'nctId': 'NCT03102450', 'acronym': 'BZK40+', 'briefTitle': 'Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age', 'organization': {'class': 'INDUSTRY', 'fullName': 'Laboratoire Innotech International'}, 'officialTitle': 'Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age', 'orgStudyIdInfo': {'id': 'PHX 401-14'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Benzalkonium Chloride Spermicide Cream', 'description': 'Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)', 'interventionNames': ['Drug: Benzalkonium Chloride Spermicide Cream']}], 'interventions': [{'name': 'Benzalkonium Chloride Spermicide Cream', 'type': 'DRUG', 'otherNames': ['Pharmatex 1,2% vaginal cream'], 'description': 'One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.\n\nDuration of treatment : 6 months (12 months optional)', 'armGroupLabels': ['Benzalkonium Chloride Spermicide Cream']}]}, 'contactsLocationsModule': {'locations': [{'zip': '13470', 'city': 'Carnoux-en-Provence', 'country': 'France', 'facility': 'Cabinet Gynecologie', 'geoPoint': {'lat': 43.25639, 'lon': 5.56444}}, {'zip': '69130', 'city': 'Écully', 'country': 'France', 'facility': 'Cabinet de Gynecologie', 'geoPoint': {'lat': 45.77437, 'lon': 4.77758}}, {'zip': '69009', 'city': 'Lyon', 'country': 'France', 'facility': 'Cabinet de Gynecologie', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '69009', 'city': 'Lyon', 'country': 'France', 'facility': 'Cabinet Gynecologie', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '13008', 'city': 'Marseille', 'country': 'France', 'facility': 'Cabinet de Gynecologie', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '44000', 'city': 'Nantes', 'country': 'France', 'facility': 'Cabinet de Gynecologie', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '92200', 'city': 'Neuilly-sur-Seine', 'country': 'France', 'facility': 'Cabinet Gynecologie', 'geoPoint': {'lat': 48.8846, 'lon': 2.26965}}, {'zip': '45100', 'city': 'Orléans', 'country': 'France', 'facility': 'Cabinet Gynecologie', 'geoPoint': {'lat': 47.90248, 'lon': 1.90407}}, {'zip': '75016', 'city': 'Paris', 'country': 'France', 'facility': 'Cabinet Gynecologie', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '67000', 'city': 'Strasbourg', 'country': 'France', 'facility': 'Cabinet Gynecologique', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '119192', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Closed Joint-Stock Company "Heirs"/Nasledniki Ltd.', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': '"The Pirogov Russian National Research Medical University"', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'A.I. Yevdokimov Moscow State University of Medicine and Dentistry"', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'FSBI "Scientific Center of Obstetrics, Gynecology and Perinatology n.a. V.I. Kulakov"', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'I.M. Sechenov First Moscow State Medical University"', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}], 'overallOfficials': [{'name': 'David Serfaty, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': '9 rue Villersexel 75007 PARIS'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Laboratoire Innotech International', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'ITEC Services', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}